Concern Over Biosimilar-To-Biosimilar Switch Could Impact Approval, US FDA Official Says

OTBB Director Sarah Yim tells the Pink Sheet that FDA cannot make an official determination that biosimilar-to-biosimilar switches are acceptable, but the agency does think about how a product will be used in the market while assessing the application.